



The Company Announcements Platform
ASX Ltd
Sydney NSW 2000

PHYLOGICA GRANTED PATENT FOR SYNTHETIC PHYLOMER[®] LIBRARIES

PERTH, AUSTRALIA: April 26, 2012 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that it has been granted a new patent (AU: 2007218045), by the Australian Patent Office. This worldwide patent (WIPO: WO200/097923) is pending in multiple other jurisdictions, including the USA, Europe and Japan. The patent covers methods of producing designed, synthetic libraries of peptides that are predicted to be rich in structure and, therefore, more likely to be drug-like than conventional random peptides.

There are numerous applications of the newly patented technology, including the rational design of Phylomer libraries in parallel formats on solid surfaces, such as peptide arrays or beads. Array formats enable tens of thousands of peptides to be screened against multiple targets on a single miniature ‘chip’, significantly reducing the time and cost of identifying relevant drug candidates. The technology is highly amenable to scaling using multiple chips to screen hundreds of thousands to millions of peptides at a time. The technology also enhances various value-added uses of the Company’s platform, including direct phenotypic screening of Phylomer libraries for the discovery of, for example, novel antivirals, antibiotics or anticancer agents. In addition, array formats facilitate the construction of a range of high-density Phylomer libraries, which can be used for new applications of the platform, such as the identification of disease biomarkers for the development of novel diagnostic products.

Dr Paul Watt, Phylogica’s Chief Executive Officer, commented on the news: “The allowance of this patent adds another powerful component to Phylogica’s Phylomer platform and opens up new opportunities in the emerging field of synthetic biology. This patent further strengthens our core IP portfolio, which already includes multiple granted worldwide patents. It maintains Phylogica’s dominant intellectual property position over the construction and screening of the world’s most structurally diverse source of peptides.”

-ends-

For further information, please contact:

Nick Woolf
CFO & VP, Corporate Development
Tel: +61 417 986 005
nwoolf@phylogica.com



Rudi Michelson
Monsoon Communications
Tel + 61 3 9620 3333

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia, and the UK, with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer[®] libraries of natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer[®] libraries and proprietary screening technologies. Its current partners include Roche, MedImmune (the worldwide biologics arm of AstraZeneca), Pfizer and Janssen (the pharmaceutical arm of Johnson & Johnson).

About Phylomer[®] Peptides

Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly, and specifically to disease associated target proteins, both inside and outside cells. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases, such as infectious diseases, cancer, autoimmunity and heart disease. Phylomer peptides can have drug-like properties, including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery approaches.